Longitudinal urinary neopterin is associated with hearing threshold change over time in independent older adults.
Age-related hearing loss
Chronic inflammation
Inflammaging
Risk stratification
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
13 06 2024
13 06 2024
Historique:
received:
04
10
2023
accepted:
11
06
2024
medline:
14
6
2024
pubmed:
14
6
2024
entrez:
13
6
2024
Statut:
epublish
Résumé
Low-grade chronic inflammation is associated with many age-related conditions. Non-invasive methods to monitor low-grade chronic inflammation may improve the management of older people at risk of poorer outcomes. This longitudinal cohort study has determined baseline inflammation using neopterin volatility in monthly urine samples of 45 independent older adults (aged 65-75 years). Measurement of neopterin, an inflammatory metabolite, enabled stratification of individuals into risk categories based on how often in a 12-month period their neopterin level was raised. Hearing was measured (pure-tone audiometry) at baseline, 1 year and 3 years of the study. Results show that those in the highest risk category (neopterin raised greater than 50% of the time) saw greater deterioration, particularly in high-frequency, hearing. A one-way Welch's ANOVA showed a significant difference between the risk categories for change in high-frequency hearing (W (3, 19.6) = 9.164, p = 0.0005). Despite the study size and duration individuals in the highest risk category were more than twice as likely to have an additional age-related morbidity than those in the lowest risk category. We conclude that volatility of neopterin in urine may enable stratification of those at greatest risk of progression of hearing loss.
Identifiants
pubmed: 38871776
doi: 10.1038/s41598-024-64648-7
pii: 10.1038/s41598-024-64648-7
doi:
Substances chimiques
Neopterin
670-65-5
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
13685Subventions
Organisme : European Research Council
ID : 638258
Pays : International
Informations de copyright
© 2024. The Author(s).
Références
Mathers, C. D. & Loncar, D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 3, e442 (2006).
doi: 10.1371/journal.pmed.0030442
pubmed: 17132052
pmcid: 1664601
Gates, G. A. & Mills, J. H. Presbycusis. The Lancet 366, 1111–1120 (2005).
doi: 10.1016/S0140-6736(05)67423-5
Wang, J. et al. Inflammation and hearing status in mid-childhood and mid-life: a population-based cross-sectional study. Int. J. Epidemiol. 48(5), 1556–1566 (2019).
doi: 10.1093/ije/dyz023
pubmed: 30815675
Verschuur, C., Agyemang-Prempeh, A. & Newman, T. A. Inflammation is associated with a worsening of presbycusis: evidence from the MRC national study of hearing. Int. J. Audiol. 53, 469–475. https://doi.org/10.3109/14992027.2014.891057 (2014).
doi: 10.3109/14992027.2014.891057
pubmed: 24679110
Nash, S. D. et al. Long-term assessment of systemic inflammation and the cumulative incidence of age-related hearing impairment in the epidemiology of hearing loss study. J. Gerontol. Series a-Biol. Sci. Med. Sci. 69, 207–214. https://doi.org/10.1093/gerona/glt075 (2014).
doi: 10.1093/gerona/glt075
Verschuur, C. A. et al. Markers of inflammatory status are associated with hearing threshold in older people: findings from the Hertfordshire ageing study. Age Ageing 41, 92–97. https://doi.org/10.1093/ageing/afr140 (2012).
doi: 10.1093/ageing/afr140
pubmed: 22086966
Simpson, A. N., Matthews, L. J. & Dubno, J. R. Lipid and C-reactive protein levels as risk factors for hearing loss in older adults. Otolaryngol.-Head Neck Surg. 148, 664–670. https://doi.org/10.1177/0194599812473936 (2013).
doi: 10.1177/0194599812473936
pubmed: 23322627
Gupta, S., Curhan, S. G. & Curhan, G. C. Biomarkers of systemic inflammation and risk of incident hearing loss. Ear Hear. 40, 981–989 (2019).
doi: 10.1097/AUD.0000000000000678
pubmed: 30399011
pmcid: 6500774
Mitchell, P. et al. Relationship of Type 2 diabetes to the prevalence, incidence and progression of age-related hearing loss. Diabetic Med. 26, 483–488 (2009).
doi: 10.1111/j.1464-5491.2009.02710.x
pubmed: 19646187
Kim, M.-B. et al. Diabetes mellitus and the incidence of hearing loss: a cohort study. Int. J. Epidemiol. 46, 717–726. https://doi.org/10.1093/ije/dyw243 (2016).
doi: 10.1093/ije/dyw243
pmcid: 6251644
Rosenhall, U. & Sundh, V. Age-related hearing loss and blood pressure. Noise Health 8, 88 (2006).
doi: 10.4103/1463-1741.33539
pubmed: 17687184
Tan, H. E. et al. Associations between cardiovascular disease and its risk factors with hearing loss—A cross-sectional analysis. Clin. Otolaryngol. 43, 172–181. https://doi.org/10.1111/coa.12936 (2018).
doi: 10.1111/coa.12936
pubmed: 28703883
Wattamwar, K. et al. Association of cardiovascular comorbidities with hearing loss in the older old. JAMA Otolaryngol. Head Neck Surg. 144, 623–629. https://doi.org/10.1001/jamaoto.2018.0643 (2018).
doi: 10.1001/jamaoto.2018.0643
pubmed: 29902313
Perry, D. P. Introduction to aging, cancer, and age-related diseases. Ann. New York Acad. Sci. 1197, vii–x. https://doi.org/10.1111/j.1749-6632.2009.05394.x (2010).
doi: 10.1111/j.1749-6632.2009.05394.x
Lin, F. R. et al. Hearing loss and incident dementia. Arch. Neurol. 68, 214–220 (2011).
doi: 10.1001/archneurol.2010.362
pubmed: 21320988
pmcid: 3277836
Lin, F. R. et al. Hearing loss and cognitive decline in older adults. JAMA Internal Med. 173, 293–299 (2013).
doi: 10.1001/jamainternmed.2013.1868
Kamil, R. J. et al. Association of hearing impairment with incident frailty and falls in older adults. J. Aging Health 28, 644–660. https://doi.org/10.1177/0898264315608730 (2016).
doi: 10.1177/0898264315608730
pubmed: 26438083
Stucky, S. R., Wolf, K. E. & Kuo, T. The economic effect of age-related hearing loss: national, state, and local estimates, 2002 and 2030. J. Am. Geriatrics Soc. 58, 618–619. https://doi.org/10.1111/j.1532-5415.2010.02746.x (2010).
doi: 10.1111/j.1532-5415.2010.02746.x
Campisi, J. et al. From discoveries in ageing research to therapeutics for healthy ageing. Nature 571, 183–192. https://doi.org/10.1038/s41586-019-1365-2 (2019).
doi: 10.1038/s41586-019-1365-2
pubmed: 31292558
pmcid: 7205183
Verschuur, C., Agyemang-Prempeh, A. & Newman, T. A. Inflammation is associated with a worsening of presbycusis: evidence from the MRC national study of hearing. Int. J. Audiol. https://doi.org/10.3109/14992027.2014.891057 (2014).
doi: 10.3109/14992027.2014.891057
pubmed: 24679110
Kociszewska, D. & Vlajkovic, S. Age-related hearing loss: the link between inflammaging, immunosenescence, and gut dysbiosis. Int. J. Mol. Sci. 23(13), 7348 (2022).
doi: 10.3390/ijms23137348
pubmed: 35806352
pmcid: 9266910
Franceschi, C. et al. Inflamm-aging: an evolutionary perspective on immunosenescence. Ann. New York Acad. Sci. 908, 244–254 (2000).
doi: 10.1111/j.1749-6632.2000.tb06651.x
Leonardi, G. C., Accardi, G., Monastero, R., Nicoletti, F. & Libra, M. Ageing: from inflammation to cancer. Immun. Ageing 15, 1. https://doi.org/10.1186/s12979-017-0112-5 (2018).
doi: 10.1186/s12979-017-0112-5
pubmed: 29387133
pmcid: 5775596
Libby, P., Okamoto, Y., Rocha, V. Z. & Folco, E. Inflammation in atherosclerosis: transition from theory to practice. Circulat. J. 74, 213–220 (2010).
doi: 10.1253/circj.CJ-09-0706
Paolisso, G. et al. Advancing age and insulin resistance: role of plasma tumor necrosis factor-α. Am. J. Physiol.-Endocrinol. Metabolism 275, E294–E299 (1998).
doi: 10.1152/ajpendo.1998.275.2.E294
Watson, N., Ding, B., Zhu, X. & Frisina, R. D. Chronic inflammation – inflammaging – in the ageing cochlea: a novel target for future presbycusis therapy. Ageing Res. Rev. 40, 142–148. https://doi.org/10.1016/j.arr.2017.10.002 (2017).
doi: 10.1016/j.arr.2017.10.002
pubmed: 29017893
pmcid: 5675822
Gale, C. R., Baylis, D., Cooper, C. & Sayer, A. A. Inflammatory markers and incident frailty in men and women: the english longitudinal study of ageing. Age 35, 2493–2501 (2013).
doi: 10.1007/s11357-013-9528-9
pubmed: 23543263
pmcid: 3751755
Baylis, D. et al. Immune-endocrine biomarkers as predictors of frailty and mortality: a 10-year longitudinal study in community-dwelling older people. Age 35, 963–971 (2013).
doi: 10.1007/s11357-012-9396-8
pubmed: 22388931
Stuart, C. M. et al. High-Throughput urinary neopterin-to-creatinine ratio monitoring of systemic inflammation. J. Appl. Lab. Med. 5, 101–113. https://doi.org/10.1373/jalm.2019.030007 (2019).
doi: 10.1373/jalm.2019.030007
Fuchs, D., Weiss, G., Reibnegger, G. & Wachter, H. The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases. Critical Rev. Clin. Lab. Sci. 29, 307–344 (1992).
doi: 10.3109/10408369209114604
Fuchs, D. et al. Neopterin--Its clinical use in urinalysis. Kidney International Supplement (1994).
Wietlicka-Kokoszanek, I. et al. Neopterin as a prognostic marker in patients with chronic heart failure. Med. Sci. Monitor: Int. Med. J. Exp. Clin. Res. 16(5), 232–237 (2010).
Nancey, S. et al. Urinary neopterin is a valuable tool in monitoring Crohn’s disease activity. Inflam. Bowel Dis. 14, 1548–1554 (2008).
doi: 10.1002/ibd.20510
DeBoer, M. D. Obesity, systemic inflammation, and increased risk for cardiovascular disease and diabetes among adolescents: a need for screening tools to target interventions. Nutrition 29, 379–386 (2013).
doi: 10.1016/j.nut.2012.07.003
pubmed: 23022122
Valdiglesias, V. et al. Immune biomarkers in older adults: Role of physical activity. J. Toxicol. Environ. Health, Part A 80, 605–620. https://doi.org/10.1080/15287394.2017.1286898 (2017).
doi: 10.1080/15287394.2017.1286898
Lee, I.-M. et al. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet 380, 219–229 (2012).
doi: 10.1016/S0140-6736(12)61031-9
pubmed: 22818936
pmcid: 3645500
Duggal, N. A., Pollock, R. D., Lazarus, N. R., Harridge, S. & Lord, J. M. Major features of immunesenescence, including reduced thymic output, are ameliorated by high levels of physical activity in adulthood. Aging cell 17, e12750 (2018).
doi: 10.1111/acel.12750
pubmed: 29517845
pmcid: 5847865
Stessman, J., Hammerman-Rozenberg, R., Cohen, A., Ein-Mor, E. & Jacobs, J. M. Physical activity, function, and longevity among the very old. Arch. Internal Med. 169, 1476–1483 (2009).
doi: 10.1001/archinternmed.2009.248
Colman, R. J. et al. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 325, 201–204 (2009).
doi: 10.1126/science.1173635
pubmed: 19590001
pmcid: 2812811
Belsky, D. W., Huffman, K. M., Pieper, C. F., Shalev, I. & Kraus, W. E. Change in the rate of biological aging in response to caloric restriction: CALERIE Biobank analysis. J Gerontol.: Series A 73, 4–10 (2017).
doi: 10.1093/gerona/glx096
Harrison, D. E. et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460, 392 (2009).
doi: 10.1038/nature08221
pubmed: 19587680
pmcid: 2786175
Martin-Montalvo, A. et al. Metformin improves healthspan and lifespan in mice. Nat. Commun. 4, 2192 (2013).
doi: 10.1038/ncomms3192
pubmed: 23900241
Group & U. P. D. S,. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352, 854–865 (1998).
doi: 10.1016/S0140-6736(98)07037-8
Knowler, W. C. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England J. Med. 346, 393–403 (2002).
doi: 10.1056/NEJMoa012512
Barzilai, N., Crandall, J. P., Kritchevsky, S. B. & Espeland, M. A. Metformin as a tool to target aging. Cell Metabolism 23, 1060–1065 (2016).
doi: 10.1016/j.cmet.2016.05.011
pubmed: 27304507
pmcid: 5943638
Montecucco, F. & Mach, F. in Seminars in immunopathology. 127–142 (Springer).
Mora, S. et al. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from JUPITER and meta-analysis of women from primary prevention trials. Circulation 121, 1069 (2010).
doi: 10.1161/CIRCULATIONAHA.109.906479
pubmed: 20176986
pmcid: 4439924
Lowthian, J. A. et al. Slowing the progression of age-related hearing loss: Rationale and study design of the ASPIRIN in HEARING, retinal vessels imaging and neurocognition in older generations (ASPREE-HEARING) trial. Contempor. Clin. Trials 46, 60–66 (2016).
doi: 10.1016/j.cct.2015.11.014
Audiology, B. & Committee, B. P. P. Recommended Procedure Pure-Tone Airconduction and Bone-Conduction Threshold Audiometry With and Without Masking (The British Society of Audiology, 2018).
Barnett, K. et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 380, 37–43. https://doi.org/10.1016/S0140-6736(12)60240-2 (2012).
doi: 10.1016/S0140-6736(12)60240-2
pubmed: 22579043
DavIs, A. C. The prevalence of hearing impairment and reported hearing disability among adults in Great Britain. Int. J. Epidemiol. 18, 911–917 (1989).
doi: 10.1093/ije/18.4.911
pubmed: 2621028
Cruickshanks, K. J. et al. Prevalence of hearing loss in older adults in Beaver Dam, Wisconsin: the epidemiology of hearing loss study. Am. J. Epidemiol. 148, 879–886 (1998).
doi: 10.1093/oxfordjournals.aje.a009713
pubmed: 9801018
Huang, Q. & Tang, J. Age-related hearing loss or presbycusis. Eur. Arch. Oto-Rhino-Laryngol. 267, 1179–1191 (2010).
doi: 10.1007/s00405-010-1270-7
Gacek, R. R. & Schuknecht, H. F. Pathology of presbycusis. Int. Audiol. 8, 199–209 (1969).
doi: 10.3109/05384916909079061
Perry, V. H., Cunningham, C. & Holmes, C. Systemic infections and inflammation affect chronic neurodegeneration. Nat. Rev. Immunol. 7, 161–167. https://doi.org/10.1038/nri2015 (2007).
doi: 10.1038/nri2015
pubmed: 17220915